Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cybin Inc. < Previous 1 2 3 4 5 6 Next > Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022 June 16, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder June 09, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Acquires DMT Clinical Study from Entheon Biomedical June 07, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievements June 03, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program June 03, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy June 02, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Host Key Opinion Leader Webinar on June 9, 2022 June 02, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022 May 17, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022 May 11, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine May 05, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022 April 22, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder April 21, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT April 13, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules April 08, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022 April 06, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievement April 01, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain March 31, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial March 29, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievement March 25, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants March 24, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022 March 16, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievement February 18, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in Aegis Virtual Conference on February 24, 2022 February 15, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights February 10, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders February 09, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievement January 27, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022 January 27, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain January 11, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Additional Adelia Milestone Achievement January 06, 2022 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Provides 2021 Year End Summary December 22, 2021 From Cybin Inc. Via Business Wire Tickers CYBN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.